AU2001271731A1 - PD-L2 molecules: novel PD-1 ligands and uses therefor - Google Patents

PD-L2 molecules: novel PD-1 ligands and uses therefor

Info

Publication number
AU2001271731A1
AU2001271731A1 AU2001271731A AU7173101A AU2001271731A1 AU 2001271731 A1 AU2001271731 A1 AU 2001271731A1 AU 2001271731 A AU2001271731 A AU 2001271731A AU 7173101 A AU7173101 A AU 7173101A AU 2001271731 A1 AU2001271731 A1 AU 2001271731A1
Authority
AU
Australia
Prior art keywords
polypeptide
nucleic acid
cell
seq
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001271731A
Other languages
English (en)
Inventor
Irene Chernova
Tatyana Chernova
Gordon Freeman
Nelly Malenkovich
Clive Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Genetics Institute LLC
Original Assignee
Dana Farber Cancer Institute Inc
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Genetics Institute LLC filed Critical Dana Farber Cancer Institute Inc
Publication of AU2001271731A1 publication Critical patent/AU2001271731A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
AU2001271731A 2000-06-28 2001-06-28 PD-L2 molecules: novel PD-1 ligands and uses therefor Abandoned AU2001271731A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21456300P 2000-06-28 2000-06-28
US60/214,563 2000-06-28
US27111401P 2001-02-23 2001-02-23
US27082201P 2001-02-23 2001-02-23
US60/270,822 2001-02-23
US60/271,114 2001-02-23
PCT/US2001/020964 WO2002000730A2 (en) 2000-06-28 2001-06-28 Pd-l2 molecules: novel pd-1 ligands and uses therefor

Publications (1)

Publication Number Publication Date
AU2001271731A1 true AU2001271731A1 (en) 2002-01-08

Family

ID=27396001

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001271731A Abandoned AU2001271731A1 (en) 2000-06-28 2001-06-28 PD-L2 molecules: novel PD-1 ligands and uses therefor
AU2001273096A Ceased AU2001273096B8 (en) 2000-06-28 2001-06-28 PD-L2 molecules: novel PD-1 ligands and uses therefor
AU7309601A Pending AU7309601A (en) 2000-06-28 2001-06-28 Pd-l2 molecules: novel pd-1 ligands and uses therefor

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2001273096A Ceased AU2001273096B8 (en) 2000-06-28 2001-06-28 PD-L2 molecules: novel PD-1 ligands and uses therefor
AU7309601A Pending AU7309601A (en) 2000-06-28 2001-06-28 Pd-l2 molecules: novel pd-1 ligands and uses therefor

Country Status (8)

Country Link
US (3) US7432059B2 (cg-RX-API-DMAC7.html)
EP (2) EP1297135B1 (cg-RX-API-DMAC7.html)
JP (2) JP2004501624A (cg-RX-API-DMAC7.html)
AU (3) AU2001271731A1 (cg-RX-API-DMAC7.html)
CA (2) CA2414331C (cg-RX-API-DMAC7.html)
ES (1) ES2402546T3 (cg-RX-API-DMAC7.html)
NZ (2) NZ522844A (cg-RX-API-DMAC7.html)
WO (2) WO2002000692A2 (cg-RX-API-DMAC7.html)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
JP2004500863A (ja) 2000-06-06 2004-01-15 ブリストル−マイヤーズ　スクイブ　カンパニー 免疫調節に有用なｂ７関連核酸およびポリペプチド
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1892251A3 (en) * 2000-06-06 2008-12-31 Brystol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
NZ522844A (en) 2000-06-28 2005-02-25 Brigham & Womens Hospital PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation
US6635750B1 (en) * 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
ES2372522T3 (es) * 2000-09-20 2012-01-23 Amgen Inc. Moléculas de tipo b7 y usos de las mismas.
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
CA2466279A1 (en) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US7595048B2 (en) * 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
US7052694B2 (en) * 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
CA2572098C (en) * 2004-06-30 2015-01-27 Mayo Foundation For Medical Education And Research B7-dc binding antibody
US20060099203A1 (en) * 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
US7501119B2 (en) * 2004-06-30 2009-03-10 Mayo Foundation For Medical Education And Research Methods and molecules for modulating an immune response
JP5303146B2 (ja) 2004-10-06 2013-10-02 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｂ７−ｈ１ならびに癌の診断、予後診断および処置の方法
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
NZ601439A (en) * 2005-06-08 2012-11-30 Brigham & Womens Hospital Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
AU2012204032B2 (en) * 2005-06-08 2014-01-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007082144A2 (en) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research B7-h1 and survivin in cancer
WO2007082154A2 (en) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
EP2468765B1 (en) 2006-03-03 2015-04-22 ONO Pharmaceutical Co., Ltd. Tetramer of extracellular domain of PD-L1
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
NZ596237A (en) * 2006-12-27 2012-07-27 Dana Farber Cancer Inst Inc Compositions and methods for the treatment of infections and tumors
AU2013200388B2 (en) * 2006-12-27 2014-10-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of infections and tumors
AU2014268176B2 (en) * 2006-12-27 2016-03-31 Dana-Farber Cancer Institute, Inc Compositions and methods for the treatment of infections and tumors
US8153595B2 (en) 2007-07-13 2012-04-10 The Johns Hopkins University B7-DC variants immunogenic compositions and methods of use thereof
WO2009030285A1 (en) * 2007-09-07 2009-03-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
US20110159023A1 (en) * 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
HUE030807T2 (en) 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
WO2010107739A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
JP5960597B2 (ja) 2009-09-30 2016-08-02 メモリアル スローン−ケタリング キャンサー センター 癌治療のための併用免疫療法
US8846397B2 (en) 2010-01-20 2014-09-30 Merck Sharp & Dohme Corp. Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
CA2787783A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US9783578B2 (en) 2010-06-25 2017-10-10 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN103732238A (zh) 2011-06-08 2014-04-16 奥瑞基尼探索技术有限公司 用于免疫调节的治疗性化合物
US20130071403A1 (en) * 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013086133A1 (en) 2011-12-06 2013-06-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating viral diseases
ES2771324T3 (es) 2012-08-03 2020-07-06 Dana Farber Cancer Inst Inc Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
EP2950814A4 (en) 2013-01-31 2016-06-08 Univ Jefferson FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US10259875B2 (en) 2013-10-01 2019-04-16 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of BIM
PT3083694T (pt) 2013-12-20 2024-02-01 Intervet Int Bv Anticorpos murinos caninizados anti-pd-1 canino
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
WO2015196051A1 (en) 2014-06-19 2015-12-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
SG11201700281SA (en) * 2014-07-14 2017-02-27 Queensland Inst Med Res Galectin immunotherapy
WO2016014148A1 (en) 2014-07-23 2016-01-28 Mayo Foundation For Medical Education And Research Targeting dna-pkcs and b7-h1 to treat cancer
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
EP3229837B1 (en) * 2014-12-08 2025-02-05 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
LT3230320T (lt) 2014-12-09 2021-01-11 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną
CN114702586A (zh) 2015-03-13 2022-07-05 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
DK3273992T3 (da) 2015-03-23 2020-07-27 Jounce Therapeutics Inc Antistoffer mod ICOS
SI3283508T1 (sl) 2015-04-17 2021-09-30 Alpine Immune Sciences, Inc. Imunomodulirajoči proteini z nastavljivimi afinitetami
HK1250033A1 (zh) 2015-07-13 2018-11-23 Cytomx Therapeutics Inc. 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
CA2995502A1 (en) 2015-09-21 2017-03-30 Merck Sharp & Dohme Corp. Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof
US10947598B2 (en) 2015-09-29 2021-03-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for determining the metabolic status of lymphomas
CN108289953B (zh) 2015-09-29 2022-03-11 细胞基因公司 Pd-1结合蛋白及其使用方法
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
JP6954648B2 (ja) 2015-10-19 2021-10-27 シージー オンコロジー， インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
KR20180066236A (ko) 2015-10-22 2018-06-18 조운스 테라퓨틱스, 인크. Icos 발현을 계측하기 위한 유전자 특질
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
EP3390451B1 (en) 2015-12-18 2025-01-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
JP7126941B2 (ja) 2015-12-22 2022-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
EP3400443B1 (en) 2016-01-04 2020-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
EP3426271B1 (en) 2016-03-10 2025-08-27 CG Oncology, Inc. Methods of treating solid tumors by combination therapy
WO2017165412A2 (en) 2016-03-21 2017-09-28 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
WO2017181152A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
TWI822521B (zh) 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
EA201990747A1 (ru) 2016-09-19 2019-10-31 Способы лечения иммунных нарушений с применением белков, связывающих pd–1
EP3534950A4 (en) 2016-11-01 2020-05-06 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
EP3932432A1 (en) 2016-12-14 2022-01-05 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
IL267804B2 (en) 2017-01-09 2024-09-01 Tesaro Inc Methods for treating cancer with anti-PD-1 antibodies
CA3053812A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
WO2018170712A1 (zh) * 2017-03-20 2018-09-27 深圳市博奥康生物科技有限公司 一种人程序性死亡配体2基因基因高表达载体的构建方法及应用
EP3600427A1 (en) 2017-03-24 2020-02-05 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating melanoma
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
AU2018251987B2 (en) 2017-04-14 2024-11-28 Cg Oncology, Inc. Methods of treating bladder cancer
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
US11572541B2 (en) 2017-06-09 2023-02-07 Providence Health & Services—Oregon Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
EP3421607A1 (en) * 2017-06-29 2019-01-02 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Identification and elimination of damaged and/or senescent cells
CN107253988B (zh) * 2017-07-19 2021-01-29 福州大学 一种人源程序性死亡因子配体pd-l2蛋白的制备方法
WO2019060888A1 (en) * 2017-09-25 2019-03-28 New York University HETÉRODIMÈRE-FC FUSION PROTEINS
EP3735590A1 (en) 2018-01-04 2020-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
WO2019162325A1 (en) 2018-02-21 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
EP3883964A1 (en) 2018-11-20 2021-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
WO2020127411A1 (en) 2018-12-19 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
EP3918332B1 (en) 2019-01-30 2025-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
WO2020161083A1 (en) 2019-02-04 2020-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
WO2020165370A1 (en) 2019-02-13 2020-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
EP3938049A1 (en) 2019-03-12 2022-01-19 President and Fellows of Harvard College Methods and compositions for treating cancer
EP3963109A1 (en) 2019-04-30 2022-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
JP2022536850A (ja) 2019-06-18 2022-08-19 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
CA3143634A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
EP4037714A1 (en) 2019-10-03 2022-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
CA3157889A1 (en) 2019-10-17 2021-04-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for diagnosing nasal intestinal type adenocarcinomas
US20240122938A1 (en) 2019-10-29 2024-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating uveal melanoma
US20230346901A1 (en) 2019-12-19 2023-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions to treat cancers
EP4090770A1 (en) 2020-01-17 2022-11-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
EP4100126A1 (en) 2020-02-05 2022-12-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
WO2021170777A1 (en) 2020-02-28 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
WO2022023379A1 (en) 2020-07-28 2022-02-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for preventing and treating a cancer
AU2021344422A1 (en) 2020-09-16 2023-05-04 Gordon J. Freeman Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
US20230416838A1 (en) 2020-11-16 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
US20230416830A1 (en) 2020-11-16 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
EP4308118A1 (en) 2021-03-17 2024-01-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating melanoma
WO2022221505A2 (en) 2021-04-14 2022-10-20 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
IL307595A (en) 2021-04-14 2023-12-01 Aro Biotherapeutics Company FN3 RNA-silencing region conjugates and their uses
US20240158861A1 (en) 2021-04-23 2024-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cell senescence accumulation related disease
EP4351595A1 (en) 2021-06-07 2024-04-17 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
CN116063401B (zh) * 2021-08-13 2023-12-01 中国人民解放军总医院 阻断型靶向pd-l1的超高亲和力小蛋白及用途
EP4427044A1 (en) 2021-11-03 2024-09-11 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating triple negative breast cancer (tnbc)
CN118613277A (zh) * 2021-12-10 2024-09-06 乔治穆内公司 多肽调节物
EP4452257A1 (en) 2021-12-21 2024-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2024033399A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
WO2024056716A1 (en) 2022-09-14 2024-03-21 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
EP4605000A1 (en) 2022-10-21 2025-08-27 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
WO2024161015A1 (en) 2023-02-03 2024-08-08 Institut National de la Santé et de la Recherche Médicale Method to treat age-related diseases
WO2024200571A1 (en) 2023-03-28 2024-10-03 Institut National de la Santé et de la Recherche Médicale Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
WO2024215976A1 (en) * 2023-04-13 2024-10-17 President And Fellows Of Harvard College Dendritic cell-based composition and method of use thereof
WO2024231384A1 (en) 2023-05-10 2024-11-14 Institut National de la Santé et de la Recherche Médicale Compositions for treating senescence related disease
WO2024236156A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d antibodies
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
WO2024256635A1 (en) 2023-06-15 2024-12-19 Institut National de la Santé et de la Recherche Médicale Dpm1 inhibitor for treating cancer
WO2025068180A1 (en) 2023-09-25 2025-04-03 Institut National de la Santé et de la Recherche Médicale Methods of treatment of cancer by targetting cancer - associated fibroblasts
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
WO2025132479A1 (en) 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization
WO2025132770A1 (en) 2023-12-22 2025-06-26 Institut National de la Santé et de la Recherche Médicale Affitins for the treatment of cancer
WO2025186778A1 (en) 2024-03-08 2025-09-12 Janssen Biotech, Inc. Combinations of oncolytic viruses and immunomodulators
WO2025212859A1 (en) * 2024-04-03 2025-10-09 Solid Biosciences, Inc. Methods and constructs for increasing solid organ transplant survival
WO2025210123A1 (en) 2024-04-03 2025-10-09 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating cancers
WO2025219330A1 (en) 2024-04-15 2025-10-23 Institut National de la Santé et de la Recherche Médicale Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
WO2025228998A1 (en) 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma
WO2025247829A1 (en) 2024-05-27 2025-12-04 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating prostate cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5521288A (en) 1990-03-26 1996-05-28 Bristol-Myers Squibb Company CD28IG fusion protein
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
US5658727A (en) 1991-04-10 1997-08-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU7405294A (en) * 1993-07-26 1995-02-20 Dana-Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor
JPH07291996A (ja) * 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5936704A (en) * 1997-12-22 1999-08-10 Gabrielian; Grant Marked contact lens bearing optical marking element
ATE397457T1 (de) * 1998-12-03 2008-06-15 Univ California Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen
AU3899700A (en) * 1999-03-17 2000-10-04 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
EP2028190A1 (en) * 1999-04-02 2009-02-25 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
AU784062B2 (en) 1999-08-23 2006-01-19 Dana-Farber Cancer Institute, Inc. Novel B7-4 molecules and uses therefor
PT1210428E (pt) * 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
EP1244683A4 (en) * 1999-11-12 2005-01-12 Human Genome Sciences Inc 21 HUMAN SECRETED PROTEINS
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
JP2004500863A (ja) 2000-06-06 2004-01-15 ブリストル−マイヤーズ　スクイブ　カンパニー 免疫調節に有用なｂ７関連核酸およびポリペプチド
NZ522844A (en) * 2000-06-28 2005-02-25 Brigham & Womens Hospital PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
CA2466279A1 (en) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof

Also Published As

Publication number Publication date
WO2002000730A2 (en) 2002-01-03
CA2414331C (en) 2011-11-29
US20080118511A1 (en) 2008-05-22
WO2002000730A9 (en) 2003-07-10
AU2001273096B2 (en) 2005-09-29
CA2413857C (en) 2010-04-27
WO2002000692A2 (en) 2002-01-03
NZ543512A (en) 2008-12-24
JP2004501631A (ja) 2004-01-22
US7709214B2 (en) 2010-05-04
US7432059B2 (en) 2008-10-07
ES2402546T3 (es) 2013-05-06
AU2001273096B8 (en) 2005-10-13
EP1297135B1 (en) 2013-01-09
WO2002000692A9 (en) 2003-05-30
US20020164600A1 (en) 2002-11-07
EP1320599A2 (en) 2003-06-25
CA2414331A1 (en) 2002-01-03
US20020110836A1 (en) 2002-08-15
WO2002000730A3 (en) 2002-11-21
CA2413857A1 (en) 2002-01-03
JP2004501624A (ja) 2004-01-22
WO2002000692A3 (en) 2003-03-27
EP1297135A2 (en) 2003-04-02
AU7309601A (en) 2002-01-08
NZ522844A (en) 2005-02-25

Similar Documents

Publication Publication Date Title
EP1297135B1 (en) Pd-l2 molecules: novel pd-1 ligands and uses therefor
EP1210428B1 (en) Pd-1, a receptor for b7-4, and uses therefor
AU2001273096A1 (en) PD-L2 molecules: novel PD-1 ligands and uses therefor
US7700301B2 (en) Methods for screening for compounds that modulate PD-1 signaling
WO2002078731A1 (en) Module of pd-1 interactions with its ligands
AU2005220184B2 (en) PD-L2 molecules: novel PD-1 ligands and uses therefor
AU2005248958A1 (en) PD-L2 molecules: novel PD-1 ligands and uses therefor
AU2002307063B2 (en) Module of PD-1 interactions with its ligands
HK1161299A (en) Assays for screening anti-pd-1 antibodies and uses thereof
AU2002307063A1 (en) Module of PD-1 interactions with its ligands